<DOC>
	<DOCNO>NCT01438125</DOCNO>
	<brief_summary>The objective study evaluate safety preliminary efficacy MF-4181 , hydrogel scaffold , improve scar result consequence follow abdominoplasty laparoscopy/laparotomy gynecologic procedure .</brief_summary>
	<brief_title>MF-4181 Reduction Scars Secondary Abdominoplasty Laparoscopy/Laparotomy Gynecologic Procedures</brief_title>
	<detailed_description />
	<criteria>Male female subject 18 60 year age undergoing abdominoplasty without intraoperative flexion time skin excision OR female subject 18 60 year age undergoing diagnostic and/or operative laparoscopy/laparotomy gynecologic procedure . Weight 50 95 kg BMI 20 30 Able willing give write informed consent Willing comply followup schedule Need concomitant surgical procedure would perform time index surgical procedure would influence heal process Previous abdominal surgery scar adhesion would limit complicate index surgical procedure Presence ventral umbilical hernia require use prosthetic material Heart disease Pregnant planning become pregnant course study ; exception exclusion ectopic pregnancy reason procedure History coagulopathy bleed disorder An American Society Anesthesiologists ( ASA ) Score &gt; II Known diabetes Current history heavy smoking ( i.e. , 10 pack year ) Active skin disorder condition may interfere heal history condition Planned use ONQ® pain control device ( IFlow Corporation , Lake Forest , CA ) similar incisional intervention post index procedure Active collagen vascular disease vasculitis , e.g. , systemic lupus erythematosus , polyarteritis , dermatomyositis , systemic scleroderma thrombotic thrombocytopenic purpura Anticipated use DERMABOND® another topical skin adhesive type wound closure Unwilling unable return followup visit Regular , continuous use systemic corticosteroid therapy topical corticosteroid use area treat Current participation participation within last 3 month study investigational drug , device , biologic Unable unwilling follow postoperative instruction Known hypersensitivity MF4181 , dextran , constituent material Previous participation study avoid multiple enrollment individual subject . Chemotherapy hormone therapy cancer within last 3 month , probability treatment require 6 month study participation . Current past radiation therapy abdominal incision</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>